Search

everythinglearnresearchcommunity

for

Search:↓

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

Tofacitinib might be used to treat hair loss.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Guilu Erxian Glue may help reduce chemotherapy side effects like weight loss and heart stress.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

The FDA approved a new Pfizer drug for hair loss in teens.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Alpha-tocopherol does not prevent hair loss from doxorubicin.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

BMS-470539 reduces skin fibrosis and inflammation.

JAK inhibitors may help improve symptoms in adults with APECED.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.